ORLYNVAH (Probenecid; Sulopenem Etzadroxil) Patent Expiration, LOE Window & CMS Spending

ORLYNVAH (Probenecid; Sulopenem Etzadroxil) by Iterum Therapeutics Us: FDA Orange Book core substance LOE 2039-12-23, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $2,975 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIterum Therapeutics Us
FDA Application & PathwayN213972 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-12-23
Last Listed Patent or Exclusivity Date2039-12-23
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,975 intro WAC)